Article Sidebar
Published:
Aug 2, 2017Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Mitigation of monocyte inflammation by inhibition of sodium phosphate co-transporter with phosphonoformic acid and parthenolide in diabetic nephropathy uremia
Abstract
Purpose: To investigate the effect of sodium phosphate co-transporter (Pit-1) on the regulation of monocyte inflammation in diabetic nephropathy uremia (DNU) patients and the underlying principles of inflammatory immune response during DNU pathogenesis.
Methods: The levels of CD14+ CD16+ and Pit-1 on peripheral blood mononuclear cells (PBMC) were measured by flow cytometry. Serum C-reactive protein (CRP) and 25(OH)D3 were detected by immunoturbidimetry while IL-6 and MCP-1 were assayed with enzyme-linked immunoassay (ELISA). The amounts of vitamin D receptors (VDRs) and Pit-1 mRNA in human acute monocytic leukemia cell lines (THP-1) were determined by quantitative real-time polymerase chain reaction (qRT-PCR), while western blot was utilized for measurement of NF-κB p65 and p-STAT5.
Results: Compared to the healthy group, DNU patients showed markedly higher CD14+CD16+, Pit-1, CRP, IL-6 and MCP-1, while 25(OH) D3 was reduced. Following stimulation with PFA or PTN, comparison with DNU group revealed that THP-1 monocytes showed a significant down-regulation of Pit-1 (1.34 ± 0.06 for PFA; 1.60 ± 0.25 for PTN; p < 0.05); NF-κB p65 (2.65 ± 0.25 for PFA; 3.88 ± 0.13 for PTN; p < 0.01), p-STAT5 (2.49 ± 0.10 for PFA; 3.03 ± 0.09 for PTN; p < 0.01) and a significant decrease in levels of IL-6 (55.38 ± 3.22 for PFA, 68.68 ± 6.01 for PTN; p < 0.05); MCP-1( 39.67 ± 3.62 for PFA; 52.62 ± 5.00 for PTN; p < 0.01), except for VDR (0.64 ± 0.15 for PFA, 0.43 ± 0.03 for PTN; p < 0.05) .
Conclusion: The level of expression of Pit-1 has a positive correlation with the level of inflammatory monocytes, which indicates that Pit-1 can be used as a new biomarker for DNU diagnosis. In addition, since Pit-1 is connected to NF-κB and STAT5 signaling pathways which are critical to inflammatory immune response, development of drugs that target Pit-1 could be an approach in developing new strategies for DNU therapy.
Keywords: Pit-1, Diabetic nephropathy, Uremia, Monocytes, Inflammation, NF-κB, STAT5
